greeksoup/ stocks
Stocks / United States / IQV · Services-Commercial Physical & Biological Research · NYSE

IQVIA Holdings Inc. (IQV)

Compare with another name

IQVIA Holdings Inc. (IQV) reported revenue of $4.2 billion for Q1 FY2026, the quarter ended 31 March 2026, up 8.4% on the same quarter a year earlier. Net income was $274 million, up 10.0% on the year, and diluted earnings per share $1.61. The figures are the company's own, from the 10-Q it filed with the SEC on 5 May 2026.

Revenue$4.2 billionup 8.4%
Net income$274 millionup 10.0%
Diluted EPS$1.61
QuarterQ1 FY2026ended 31 March 2026

Ratios

From the filings

ROE22.3%
ROCE10.9%
Operating margin13.2%
Net margin8.3%
FCF margin12.7%
Interest cover2.91
Debt to equity2.25
Cash conversion1.95
Share count, 1 year-4.1%
Sales CAGR, 3 years4.2%
Profit CAGR, 3 years7.6%
EPS, TTM$8.05

At the close of 21 September 2026

Price$269.88
Market cap$45.0 billion
Stock P/E33.53
Price to book7.24
EV / EBITDA16.95
Dividend yieldn/a
Market cap / sales2.71
52-week high$271.62
52-week low$156.66
Price, 1 year44.2%
Price CAGR, 3 years10.7%
Price CAGR, 5 years0.8%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on long-term debt as IQVIA Holdings Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on IQV

Filings20 in twelve months: 12 current reports (8-K), about 4 other events; 4 results of operations; 2 material agreement; 2 new financial obligation; 2 officer or director change
Planned insider sales9 Form 144 notices in twelve months, $51.4 million; latest 2 September 2026
Options tapeput/call 0.89 by open interest on 23 September 2026; the straddle prices a 7.0% move to 16 October 2026
Holders10 of the followed funds hold it; largest Harris Associates; 2 Schedule 13D or 13G filings in twelve months
Insider trading17 sales and 0 purchases on Form 4 in twelve months
Congress1 House trade disclosed in six months
Short interest3.8 million shares short, 2.85 days to cover at 31 August 2026
Documentsthe 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

Q2 FY2023Q3 FY2023Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026
Revenue3,7283,7363,8683,7373,8143,8963,9583,8294,0174,1004,3644,151
Gross profit850862n/a827863915n/an/an/an/an/an/a
Gross margin23%23%n/a22%23%23%n/an/an/an/an/an/a
SG&A482502556508509522453508509514468502
Operating income524481501506520550626496506553627514
Operating margin14%13%13%14%14%14%16%13%13%13%14%12%
Interest expense169181181166163170171165182189193192
Pre-tax income375349373340436349544323323408537328
Tax rate22%15%-27%14%17%19%21%19%17%19%11%18%
Net income297303469288363285437249266331514274
Net margin8%8%12%8%10%7%11%7%7%8%12%7%
Diluted EPS$1.59$1.63$2.54$1.56$1.97$1.55$2.41$1.40$1.54$1.93$2.97$1.61
Operating cash flow402583747522588721885568443908735618
Capital expenditure160146179145143150164142151136174127
Free cash flow242437568377445571721426292772561491
Buybacks4901442290.00.02001,1503756570.0212552
Shares outstanding183m182m182m182m182m182m176m174m170m170m170m167m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

FY2014 FY2015 FY2016 FY2017 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Revenue5,4605,7386,8789,73910,41211,08811,35913,87414,41014,98415,40516,31016,632
Cost of revenue2,6642,7053,2364,622n/an/an/an/an/an/an/an/an/a
Gross profit2,7763,0123,6425,117n/an/an/an/an/an/an/an/an/a
Gross margin50.8%52.5%53.0%52.5%n/an/an/an/an/an/an/an/an/a
Research and development5.83.3n/an/an/an/an/an/an/an/an/an/an/a
Selling, general and administrative7818151,0161,6221,7161,7341,7891,9642,0712,0531,9921,9991,993
Operating income5906475766657417777311,3931,7991,9772,2022,1822,200
Operating margin10.8%11.3%8.4%6.8%7.1%7.0%6.4%10.0%12.5%13.2%14.3%13.4%13.2%
Interest expense101101144346414447416375416672670729756
Pre-tax income5015394162943283523731,1281,3631,4591,6691,5911,596
Income tax149159325-99259.011672.0163260101301252250
Effective tax rate29.7%29.5%78.1%-337.4%18.0%33.0%19.3%14.5%19.1%6.9%18.0%15.8%15.7%
Net income35638772.01,2772591912799661,0911,3581,3731,3601,385
Net margin6.5%6.7%1.0%13.1%2.5%1.7%2.5%7.0%7.6%9.1%8.9%8.3%8.3%
Diluted EPS$2.72$3.08$0.76$5.88$1.24$0.96$1.43$4.95$5.72$7.29$7.49$7.84$8.05
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

FY2014 FY2015 FY2016 FY2017 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Operating cash flown/an/a8609701,2541,4171,9592,9422,2602,1492,7162,6542,704
Capital expenditure83.078.0164369459582616640674649602603588
Free cash flown/an/a6966017958351,3432,3021,5861,5002,1142,0512,116
Free cash flow marginn/an/a10.1%6.2%7.6%7.5%11.8%16.6%11.0%10.0%13.7%12.6%12.7%
Depreciation and amortisation1211282891,0111,1411,2021,2871,2641,1301,1251,1141,1441,167
Share-based compensation30.038.010610611314695.0170194217206247240
Buybacks4155151,0972,6201,4059494474061,1689921,3501,2441,421
Diluted shares, weighted131m126m152m223m208m200m195m195m191m186m183m174m170m
Shares outstanding at period end124m119m248mn/a198m192m191m191m186m182m176m170m167m
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

FY2014 FY2015 FY2016 FY2017 FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025TTM
Total assets3,2963,92621,20822,85722,54923,25124,56424,68925,33726,68126,89929,94429,675
Cash and equivalents8679771,1989598918371,8141,3661,2161,3761,7021,9801,947
Receivables9751,1661,7072,0972,3942,5822,4102,5512,9173,3813,2043,4003,346
Goodwill46472010,72711,85011,80012,15912,65413,30113,92114,56714,71016,61616,544
Long-term debt2,3062,5017,21910,26910,90711,54512,38412,03412,59512,95512,83813,88413,989
Long-term debt including finance leases2,2832,4197,108n/an/an/an/an/an/an/an/an/an/a
Borrowings, as the company tags themn/an/a7,21910,26911,05611,70512,60012,18512,79713,75214,04515,80015,908
Operating lease liabilitiesn/an/an/an/an/a396371313264223173225232
Finance lease liabilitiesn/an/an/an/an/an/a122177224228218212n/a
Shareholders' equity-704-5648,6337,9956,7146,0036,0016,0425,7656,1126,0676,5036,221
Filing10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

10 years5 years3 yearsTTM
Sales growth, compounded11.0%7.5%4.2%7.3%
Profit growth, compounded13.4%37.3%7.6%3.8%
Return on equity, average12.9%20.1%21.9%20.9%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Services-Commercial Physical & Biological Research

CompanyMarket capP/EROEOp. marginSales growth
TTM
Debt to equityDiv. yield
IQVIA Holdings Inc. IQV$45.0 billion33.5322.3%13.2%7.3%2.25n/a
Incyte Corp. INCY$24.9 billion17.6125.5%30.0%21.5%9.91n/a
Charles River Laboratories International, Inc. CRL$13.3 billionn/a-8.4%2.3%-0.7%0.92n/a

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

FilingPeriodFiledWhere
10-Q30 June 202628 July 2026EDGAR
10-Q31 March 20265 May 2026EDGAR
10-K31 December 202517 February 2026EDGAR
10-Q30 September 202528 October 2025EDGAR
10-Q30 June 202522 July 2025EDGAR
10-Q31 March 20256 May 2025EDGAR
10-K31 December 202413 February 2025EDGAR
10-Q30 September 202431 October 2024EDGAR
10-Q30 June 202422 July 2024EDGAR
10-Q31 March 20242 May 2024EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install